LOW-MOLECULAR-WEIGHT HEPARINS VERSUS UNFRACTIONATED HEPARIN FOR TREATMENT OF HEMODIALYSED PATIENTS

Abstract

Prevention of clotting in hemodialysis patients with a normal risk of bleeding in accordance with procedures V.2.1 and V.2.2 respectively, it is stated that: A. In patients without an increased risk of bleeding, low doses of unfractionated heparin (NFH) or low molecular weight heparin (NMH) should be used to prevent blood clotting in the extracorporeal circulation system during the hemodialysis (HD) procedure. (level of evidence: A). Due to safety (level of evidence: A) and equal efficacy (level of evidence: A) and ease of handling (level of evidence: C), preference should be given to NMH over NFH. After administration of the first bolus of NFH, it is necessary to monitor the anticoagulation effect by determining APTV or activated clotting time (AVT).